Free shipping on all orders over $ 500

Losmapimod

Cat. No. M3751

All AbMole products are for research use only, cannot be used for human consumption.

Losmapimod Structure
Synonym:

GW-856553X; GSK-AHAB; SB856553

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 50 In stock
2mg USD 30 In stock
5mg USD 48 In stock
10mg USD 70 In stock
25mg USD 142 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Losmapimod is a promising new agent against cardiovascular diseases. This compound works by inhibiting p38 MAP kinases, which play an important role in the development of atherosclerosis and heart failure caused by ischemic conditions. The p38 MAPK inhibitor losmapimod (GW856553) attenuates the pro-inflammatory response in humans by reducing PIC production.

Product Citations
Protocol (for reference only)
Cell Experiment
Cell lines
Preparation method
Concentrations
Incubation time
Animal Experiment
Animal models Spontaneously hypertensive stroke-prone rats
Formulation
Dosages ~12 mg/kg
Administration p.o.
Chemical Information
Molecular Weight 383.46
Formula C22H26FN3O2
CAS Number 585543-15-3
Solubility (25°C) DMSO 25 mg/mL
Ethanol 30 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Waterworth DM, et al. J Am Heart Assoc. A low-frequency variant in MAPK14 provides mechanistic evidence of a link with myeloperoxidase: a prognostic cardiovascular risk marker.

[2] Newby LK, et al. Lancet. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.

[3] Inamdar A, et al. J Psychopharmacol. Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach.

[4] Dewenter M, et al. Dtsch Med Wochenschr. Losmapimod: a novel drug against cardiovascular diseases?

[5] Barbour AM, et al. Br J Clin Pharmacol. Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers.

Related p38 MAPK Products
BIRB796

BIRB 796 (Doramapimod) is a protein kinase inhibitor of p38 MAPK with Kd of 100pM.

Selonsertib

GS-4997 is a highly selective and potent once-daily oral ASK1 inhibitor with potential anti-inflammatory, antineoplastic and anti-fibrotic activities.

Adezmapimod

Adezmapimod (SB203580) is a P38 MAPK inhibitor with an IC50 of 0.3-0.5 μM, which is 10 times less selective than SAPK3(106T) and SAPK4(106T), and inhibits PKB phosphorylation with an IC50 of 3-5 μM.

SB 202190

SB 202190 is a highly selective, potent and cell permeable inhibitor of p38 MAP kinase with IC50 values of 50 and 100 nM inhibiting p38α and p38β, respectively.

PH-797804

PH-797804 is a highly selective and potent inhibitor of p38 MAP kinase with IC50 of 26 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: Losmapimod, GW-856553X; GSK-AHAB; SB856553 supplier, p38 MAPK, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.